Scholarlink

<p><b>Background</b></p><p>Theileriosis, a tick-borne disease caused by <i>Theileria annulata</i>, leads to global economic losses in livestock, emphasizing an urgent need for the identification of new therapeutic agents with alternative mechanisms of action due to rising buparvaquone resistance combined with climate-driven spread. <i>T. annulata</i> lactate dehydrogenase (<i>Ta</i>LDH) has been selected as a promising target in the current study. As approximately half of the FDA-approved veterinary drugs are shared with human medicine, integrating drug repurposing has gained importance as an emerging strategy for the management of tick-borne&#xa0;diseases. </p><p><b>Methods</b></p><p>In this study, <i>in vitro</i> and <i>in silico</i> approaches are integrated to screen 21 Active Pharmaceutical Ingredients (APIs) from FDA-approved drugs against <i>Ta</i>LDH in the context of drug repurposing. </p><p><b>Results</b> </p><p>Six of 21 the APIs showed ≥ 60% inhibition against <i>Ta</i>LDH (over 95% purity), particularly the proton pump inhibitor omeprazole, which exhibited both the highest inhibition percentage (73.36%) and the lowest binding energy (− 6.36&#xa0;kcal/mol), with a consistency between experimental and computational results. To our knowledge, this study is the first to evaluate FDA-approved human therapeutics as potential <i>Ta</i>LDH inhibitors. </p><p><b>Conclusion</b> </p><p>This preliminary <i>in vitro</i> enzymatic inhibition study suggests omeprazole as a potential therapeutic agent for theileriosis. However, comprehensive pharmacokinetic and pharmacodynamic analyses will further validate and advance these promising findings. Furthermore, APIs with ≥ 60% inhibition of <i>Ta</i>LDH may serve as promising leads for the future development of more potent anti-theilerial agents through targeted derivatization and lead optimization. In alignment with the One Health framework, evaluating human-approved active pharmaceutical ingredients as veterinary therapeutic against parasitic diseases may offer a sustainable, time and cost-efficient strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of Human-Approved Active Pharmaceutical Ingredients Against Lactate Dehydrogenase from Theileria annulata

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Selcan Akar,
  • Maria Orlenco,
  • Erennur Ugurel,
  • Özkan Danış,
  • Dilek Turgut-Balik

摘要

Background

Theileriosis, a tick-borne disease caused by Theileria annulata, leads to global economic losses in livestock, emphasizing an urgent need for the identification of new therapeutic agents with alternative mechanisms of action due to rising buparvaquone resistance combined with climate-driven spread. T. annulata lactate dehydrogenase (TaLDH) has been selected as a promising target in the current study. As approximately half of the FDA-approved veterinary drugs are shared with human medicine, integrating drug repurposing has gained importance as an emerging strategy for the management of tick-borne diseases.

Methods

In this study, in vitro and in silico approaches are integrated to screen 21 Active Pharmaceutical Ingredients (APIs) from FDA-approved drugs against TaLDH in the context of drug repurposing.

Results

Six of 21 the APIs showed ≥ 60% inhibition against TaLDH (over 95% purity), particularly the proton pump inhibitor omeprazole, which exhibited both the highest inhibition percentage (73.36%) and the lowest binding energy (− 6.36 kcal/mol), with a consistency between experimental and computational results. To our knowledge, this study is the first to evaluate FDA-approved human therapeutics as potential TaLDH inhibitors.

Conclusion

This preliminary in vitro enzymatic inhibition study suggests omeprazole as a potential therapeutic agent for theileriosis. However, comprehensive pharmacokinetic and pharmacodynamic analyses will further validate and advance these promising findings. Furthermore, APIs with ≥ 60% inhibition of TaLDH may serve as promising leads for the future development of more potent anti-theilerial agents through targeted derivatization and lead optimization. In alignment with the One Health framework, evaluating human-approved active pharmaceutical ingredients as veterinary therapeutic against parasitic diseases may offer a sustainable, time and cost-efficient strategy.